Trial · NCT06582732
Performance of the Travoprost Intraocular Implant
NCT06582732, Phase 2, Completed, Glaukos Corporation; results first posted 2024-10-15
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Performance of the Travoprost Intraocular Implant. Trials, record NCT06582732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06582732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Performance of the Travoprost Intraocular Implant
- NCT number
- NCT06582732
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 210 participants, actual
- Lead sponsor
- Glaukos Corporation
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6, Travoprost Intracameral Implant exchanged at Month 24, Travoprost intracameral implant exchanged at Month 21, Travoprost intracameral implant exchanged at Month 18, Travoprost intracameral implant exchanged at Month 15
- First posted
- 2024-09-03
- Last updated
- 2024-10-15
- Results first posted
- 2024-10-15
- Limitations and caveats
Study was open-label, non-randomized and conducted at a single site; however, the endpoints were objective and analyses of aqueous humor concentrations of travoprost free acid and of residual travoprost in explants were performed by a third party
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration | month 12 | concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS) |
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration | month 3 | concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS |
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration | month 6 | concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS |
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration | month 24 | concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS |
| Primary | Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration | month 21 | concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS |
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration | month 18 | concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS |
| Primary | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration | month 15 | concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS |
| Secondary | Percent Residual Travoprost in Explanted Implant 12 Months Post-administration | month 12 | percent of travoprost compared to baseline in explanted implant 12 months post-administration as assessed by high performance liquid chromatography (HPLC) |
| Secondary | Percent Residual Travoprost in Explanted Implant 3 Months Post-administration | month 3 | percent of travoprost compared to baseline in explanted implant 3 months post-administration as assessed by HPLC |
| Secondary | Percent Residual Travoprost in Explanted Implant 6 Months Post-administration | month 6 | percent of travoprost compared to baseline in explanted implant 6 months post-administration as assessed by HPLC |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration | month 12 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration | month 3 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration | month 6 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration | month 24 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration | month 21 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration | month 18 | study eyes | ng/mL | MEAN |
| PRIMARY | Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration | month 15 | study eyes | ng/mL | MEAN |
| SECONDARY | Percent Residual Travoprost in Explanted Implant 12 Months Post-administration | month 12 | explanted travoprost intracameral implants | percentage of initial | MEAN |
| SECONDARY | Percent Residual Travoprost in Explanted Implant 3 Months Post-administration | month 3 | explanted travoprost intracameral implants | percentage of initial | MEAN |
| SECONDARY | Percent Residual Travoprost in Explanted Implant 6 Months Post-administration | month 6 | explanted travoprost intracameral implants | percentage of initial | MEAN |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration | Cohort 1 (12-month Exchange) | 5.57 | Standard Deviation 3.02 | ng/mL | |
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration | Cohort 2 (3-month Exchange) | 4.98 | Standard Deviation 2.50 | ng/mL | |
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration | Cohort 3 (6-month Exchange) | 3.74 | Standard Deviation 2.22 | ng/mL | |
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration | Cohort 4 (24-month Exchange) | 3.35 | Standard Deviation 1.51 | ng/mL | |
| Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration | Cohort 5 (21-month Exchange) | 3.80 | Standard Deviation 1.58 | ng/mL | |
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration | Cohort 6 (18-month Exchange) | 2.22 | Standard Deviation 1.24 | ng/mL | |
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration | Cohort 7 15-month Exchange) | 2.03 | Standard Deviation 0.736 | ng/mL | |
| Percent Residual Travoprost in Explanted Implant 12 Months Post-administration | Cohort 1 (12-month Exchange) | 50.2 | Standard Deviation 6.58 | percentage of initial | |
| Percent Residual Travoprost in Explanted Implant 3 Months Post-administration | Cohort 2 (3-month Exchange) | 78.8 | Standard Error 3.15 | percentage of initial | |
| Percent Residual Travoprost in Explanted Implant 6 Months Post-administration | Cohort 3 (6-month Exchange) | 69.8 | Standard Deviation 8.51 | percentage of initial |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow42
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Study Period | STARTED | Cohort 1 (12-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 2 (3-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 3 (6-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 4 (24-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 5 (21-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 6 (18-month Exchange) | 30 | 30 |
| Initial Study Period | STARTED | Cohort 7 (15-month Exchange) | 30 | 30 |
| Initial Study Period | COMPLETED | Cohort 1 (12-month Exchange) | 29 | 29 |
| Initial Study Period | COMPLETED | Cohort 2 (3-month Exchange) | 29 | 29 |
| Initial Study Period | COMPLETED | Cohort 3 (6-month Exchange) | 28 | 28 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 participant flowAdverse events49
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Corona virus infection | Infections and infestations | Cohort 1 (12-month Exchange) | 2 | 30 | 2 |
| other | Corona virus infection | Infections and infestations | Cohort 2 (3-month Exchange) | 0 | 30 | 0 |
| other | Corona virus infection | Infections and infestations | Cohort 3 (6-month Exchange) | 3 | 30 | 3 |
| other | Corona virus infection | Infections and infestations | Cohort 4 (24-month Exchange) | 0 | 30 | 0 |
| other | Corona virus infection | Infections and infestations | Cohort 5 (21-month Exchange) | 0 | 30 | 0 |
| other | Corona virus infection | Infections and infestations | Cohort 6 (18-month Exchange) | 0 | 30 | 0 |
| other | Corona virus infection | Infections and infestations | Cohort 7 (15-month Exchange) | 0 | 30 | 0 |
| other | Influenza | Infections and infestations | Cohort 1 (12-month Exchange) | 1 | 30 | 1 |
| other | Influenza | Infections and infestations | Cohort 2 (3-month Exchange) | 0 | 30 | 0 |
| other | Influenza | Infections and infestations | Cohort 3 (6-month Exchange) | 0 | 30 | 0 |
1 to 10 of 49Source ClinicalTrials.gov
See all 49 adverse eventsAdverse event totals21
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 (12-month Exchange) | 1 | 30 |
| Total, all-cause mortality | Cohort 2 (3-month Exchange) | 0 | 30 |
| Total, all-cause mortality | Cohort 3 (6-month Exchange) | 0 | 30 |
| Total, all-cause mortality | Cohort 4 (24-month Exchange) | 0 | 30 |
| Total, all-cause mortality | Cohort 5 (21-month Exchange) | 1 | 30 |
| Total, all-cause mortality | Cohort 6 (18-month Exchange) | 0 | 30 |
| Total, all-cause mortality | Cohort 7 (15-month Exchange) | 0 | 30 |
| Total, other adverse events | Cohort 1 (12-month Exchange) | 4 | 30 |
| Total, other adverse events | Cohort 2 (3-month Exchange) | 0 | 30 |
| Total, other adverse events | Cohort 3 (6-month Exchange) | 5 | 30 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40126812 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06582732
GET https://conductscience.org/api/trials/v1/NCT06582732/flow?page=2